The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ALLAKOS INC | COM | 01671P100 | 77,318 | 17,733 | SH | SOLE | 17,733 | 0 | 0 | ||
COMPASS THERAPEUTICS INC | COM | 20454B104 | 138,220 | 43,466 | SH | SOLE | 43,466 | 0 | 0 | ||
ELEVATION ONCOLOGY INC | COM | 28623U101 | 33,022 | 21,725 | SH | SOLE | 21,725 | 0 | 0 | ||
MOLECULAR TEMPLATES INC | COM | 608550109 | 985,436 | 2,052,991 | SH | SOLE | 2,052,991 | 0 | 0 | ||
REZOLUTE INC | COM NEW | 76200L309 | 2,611,555 | 1,318,967 | SH | SOLE | 1,318,967 | 0 | 0 | ||
SAVARA INC | COM | 805111101 | 16,026,005 | 4,980,804 | SH | SOLE | 4,980,804 | 0 | 0 | ||
XERIS BIOPHARMA HOLDINGS INC | COM | 98422E103 | 14,781,830 | 5,641,920 | SH | SOLE | 5,641,920 | 0 | 0 |